Invesco Ltd. - ENANTA PHARMACEUTICALS INC ownership

ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 132 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.88 and the average weighting 0.0%.

Quarter-by-quarter ownership
Invesco Ltd. ownership history of ENANTA PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$207,382
-88.5%
18,566
-77.9%
0.00%
Q2 2023$1,800,233
-85.2%
84,123
-72.1%
0.00%
-100.0%
Q1 2023$12,203,579
+146.1%
301,770
+183.1%
0.00%
+200.0%
Q4 2022$4,958,987
-73.2%
106,599
-70.1%
0.00%
-83.3%
Q3 2022$18,474,000
-21.8%
356,177
-28.7%
0.01%
-14.3%
Q2 2022$23,613,000
-3.0%
499,530
+46.1%
0.01%
+16.7%
Q1 2022$24,343,000
+12.3%
342,007
+18.0%
0.01%
+20.0%
Q4 2021$21,674,000
+259.3%
289,844
+173.0%
0.01%
+150.0%
Q3 2021$6,032,000
-51.3%
106,168
-62.2%
0.00%
-33.3%
Q2 2021$12,374,000
-22.9%
281,164
-13.6%
0.00%
-25.0%
Q1 2021$16,057,000
-32.3%
325,556
-42.2%
0.00%
-42.9%
Q4 2020$23,711,000
-3.2%
563,211
+5.2%
0.01%
-12.5%
Q3 2020$24,503,000
+321.1%
535,215
+361.8%
0.01%
+300.0%
Q2 2020$5,819,000
-52.1%
115,903
-51.0%
0.00%
-60.0%
Q1 2020$12,155,000
-49.2%
236,344
-39.0%
0.01%
-28.6%
Q4 2019$23,936,000
+20.7%
387,439
+17.4%
0.01%
+40.0%
Q3 2019$19,823,000
-24.4%
329,940
+6.2%
0.01%
-28.6%
Q2 2019$26,218,000
-33.6%
310,717
-24.8%
0.01%
-46.2%
Q1 2019$39,481,000
+21.5%
413,327
-9.9%
0.01%
+8.3%
Q4 2018$32,508,000
-46.2%
458,956
-35.1%
0.01%
-36.8%
Q3 2018$60,431,000
+2.5%
707,113
+39.0%
0.02%
-5.0%
Q2 2018$58,941,000
+53.9%
508,541
+7.5%
0.02%
+42.9%
Q1 2018$38,289,000
+19.4%
473,228
-13.4%
0.01%
+16.7%
Q4 2017$32,081,000
-2.6%
546,699
-22.3%
0.01%0.0%
Q3 2017$32,922,000
+1027.5%
703,460
+767.0%
0.01%
+1100.0%
Q2 2017$2,920,000
+21.8%
81,137
+4.3%
0.00%0.0%
Q1 2017$2,397,000
+21.8%
77,799
+32.4%
0.00%0.0%
Q4 2016$1,968,000
+46.6%
58,766
+16.5%
0.00%
Q3 2016$1,342,000
-0.3%
50,433
-17.4%
0.00%
Q2 2016$1,346,000
-34.3%
61,041
-12.5%
0.00%
-100.0%
Q1 2016$2,049,000
-90.4%
69,754
-89.2%
0.00%
-88.9%
Q4 2015$21,415,000
-7.4%
648,558
+1.3%
0.01%
-10.0%
Q3 2015$23,138,000
-9.6%
640,224
+12.5%
0.01%0.0%
Q2 2015$25,609,000
+44.5%
569,209
-1.7%
0.01%
+42.9%
Q1 2015$17,725,000
+263.8%
578,877
+504.2%
0.01%
+250.0%
Q4 2014$4,872,000
+62.2%
95,810
+26.3%
0.00%
+100.0%
Q3 2014$3,003,000
-7.7%
75,885
+0.5%
0.00%0.0%
Q2 2014$3,252,000
+218.2%
75,501
+195.4%
0.00%
Q1 2014$1,022,00025,5620.00%
Other shareholders
ENANTA PHARMACEUTICALS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Krensavage Asset Management, LLC 862,848$42,556,00014.73%
Fairmount Funds Management LLC 171,147$8,441,0003.56%
ARMISTICE CAPITAL, LLC 1,648,000$81,279,0001.87%
FARALLON CAPITAL MANAGEMENT LLC 1,995,000$98,393,0000.49%
Jackson Creek Investment Advisors LLC 21,409$1,056,0000.37%
Hennion & Walsh Asset Management, Inc. 113,940$5,620,0000.34%
Virtus ETF Advisers LLC 14,721$726,0000.31%
Granahan Investment Management 193,416$9,539,0000.20%
Yorktown Management & Research Co Inc 4,500$222,0000.18%
JACOBS LEVY EQUITY MANAGEMENT, INC 242,257$11,948,0000.09%
View complete list of ENANTA PHARMACEUTICALS INC shareholders